Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
AKANDA CORP.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
AKANDA CORP.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
AKANDA CORP.
SIC 2833 · Medicinal Chemicals & Botanical Products
Notes
Support
about
terms
$
AKAN
AKANDA CORP.
CIK:
0001888014
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Profit or loss [abstract]
Sales
$ 258,075
Cost of sales
414,098
Gross Profit (Loss)
(156,023)
Operating expenses
Depreciation and amortization
433,693
137,271
Consulting and professional fees
1,463,786
2,377,926
Personnel expenses
624,710
495,699
General and administrative expenses
2,305,195
1,019,287
Total operating expenses
4,827,384
4,030,183
Operating loss
(4,983,407)
(4,030,183)
Other income (expenses):
Finance income
2,953
Finance expense
(925,092)
(81,083)
Foreign exchange gain (loss), net
273,606
(132,842)
Transaction costs
(350,000)
Change in fair value of financial liabilities measured at FVTPL
1,750,820
Gain (loss) on debt settlement
1,914,956
(219,719)
Other income
74,455
Gain on sale of subsidiary
198,780
Write-off of AP, net
475,816
Write-off of holdback payable
400,000
Write-off of loan receivable
(235,686)
Impairment loss
(44,812,112)
Total Other income
(42,383,508)
718,360
Net loss from continuing operations
(47,366,915)
(3,311,823)
Gain (loss) from discontinued operation
507,604
(784,206)
Net loss
(46,859,311)
(4,096,029)
Translation adjustment
(175,651)
(101,188)
Comprehensive loss
(47,034,962)
(4,197,217)
Net loss attributable to:
Shareholders of the Company
(45,653,948)
(4,096,029)
Non-controlling interest
(1,205,363)
Net loss attributable
(46,859,311)
(4,096,029)
Net comprehensive loss attributable to:
Shareholders of the Company
(46,242,254)
(4,197,217)
Non-controlling interest
(792,708)
Net comprehensive loss attributable
$ (47,034,962)
$ (4,197,217)
Loss per share from continuing operations – basic (in Dollars per share)
$ (669.58)
$ (223.48)
Loss per share from continuing operations – diluted (in Dollars per share)
(669.58)
(223.48)
Loss per share – basic (in Dollars per share)
(662.22)
(276.4)
Loss per share – diluted (in Dollars per share)
$ (662.22)
$ (276.4)
Weighted average common shares outstanding (in Shares)
68,941
14,819
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:
Net loss from continuing operations
$ (47,366,915)
$ (3,311,823)
Net gain (loss) from discontinued operations
507,604
(784,206)
Net loss for the year
(46,859,311)
(4,096,029)
Adjustments for non-cash items:
Gain on loss of control of Canmart, net of cash surrendered and foreign currency translation adjustment
(12,999)
Depreciation and amortization
433,693
137,271
Depreciation and amortization from discontinued operations
926
265,284
Interest expenses and accretion
925,092
81,083
Interest expenses from discontinued operations
143,229
Interest income from Bridge loans
(6,446)
Fair value of RSUs granted and exercised
1,547,703
Gain on settlement on debt
(1,914,956)
(27,554)
Gain on sale of subsidiary
(198,780)
Write-off of AP, net
(475,816)
Write-off of holdback payable
(400,000)
Write-off of loan receivable
235,686
Foreign exchange gain, net
(273,606)
Impairment loss
44,812,112
Change in fair value of financial liabilities at FVTPL
(1,750,820)
Working capital adjustments (net of amounts acquired/disposed):
Trade and other receivables
68,459
(254,676)
Prepayments
(1,344,237)
(285,588)
Inventory
366,215
Trade and other payables
(1,209,862)
(733,363)
Due to related parties
160,775
(42,898)
Cash flows used in operating activities
(6,729,048)
(3,980,365)
Cash flows from investing activities:
Additions to property, plant and equipment
(1,234,056)
(2,098,138)
Cash surrendered on sale of RPK
(105,175)
Net cash proceeds from sale of subsidiary
1,553,750
Loan repayment (receivable)
347
(16,602)
Cash lent for Bridge loan
(350,000)
Cash surrendered on loss of control of Canmart
(174)
Acquisition of First Towers, net of cash acquired and unpaid note consideration
(6,218,004)
Cash flows used in investing activities
(7,451,887)
(1,016,165)
Cash flows from financing activities:
Proceeds from private placement, net of costs
275,929
10,754,944
Proceeds from issuance of convertible promissory notes
12,000,000
Advances from (to) related parties
(220,030)
44,954
Repayment of advances from related parties
(62,596)
(1,470,826)
Loans received
65,282
Loans repaid
(201,206)
(104,920)
Lease payments
(113,782)
(300,000)
Cash flows provided by financing activities
11,678,315
8,989,434
Net increase (decrease) in cash and cash equivalents
(2,502,620)
3,992,904
Effects of exchange rate changes on cash and cash equivalents
(835,110)
(244,913)
Cash and cash equivalents at the beginning of the year
3,841,866
93,875
Cash and cash equivalents at the end of the year
$ 504,136
$ 3,841,866
v3.26.1
Consolidated Statements of Financial Position - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current
Cash
$ 503,562
$ 3,838,650
Cash held in trust
574
3,216
Trade and other receivables
1,399,977
370,537
Prepayments
1,698,022
391,649
Loans receivable
451,529
Total Current Assets
3,602,135
5,055,581
Non-Current
Property, plant and equipment
2,365,831
2,339,182
Intangible assets and goodwill
15,827
Loan receivable
503,493
Right-of-use assets
227,589
Total Non-Current Assets
2,593,420
2,858,502
Total Assets
6,195,555
7,914,083
Current
Trade and other payables
3,309,037
2,982,499
Lease liability
187,442
Loans and borrowings
1,006,920
352,814
Convertible promissory notes
1,055,420
Due to related parties
640,546
302,232
Total Current Liabilities
6,199,365
3,637,545
Non-Current
Lease liability
208,679
Secured promissory notes
7,633,966
Secured convertible debenture
4,143,982
Total Non-Current Liabilities
11,986,627
Total Liabilities
18,185,992
3,637,545
Shareholders’ Equity (Deficit)
Common shares
73,555,097
63,319,398
Other reserves
3,370
24,423
Accumulated deficit
(103,091,953)
(57,459,061)
Accumulated other comprehensive loss
(2,304,665)
(1,608,222)
Non-controlling interest
(1,205,363)
Total Shareholders’ Equity (Deficit)
(11,990,437)
4,276,538
Total Liabilities and Shareholders’ Equity (Deficit)
6,195,555
7,914,083
Class A special shares
Shareholders’ Equity (Deficit)
Common shares
597,836
Class B special shares
Shareholders’ Equity (Deficit)
Common shares
$ 20,455,241